OR WAIT null SECS
Bruker introduces the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications.
Characterization Solutions to Leading Pharma and Biotech PartnersBruker introduces the first software solution to encompass the complete biopharmaceutical characterization challenge, including glycoforms, impurities and modifications. The unique BioPharmaCompass 1.1 software allows biotech customers to leverage Bruker’s leadership in cutting-edge mass spectrometry for intact protein and post-translational modification analysis in a routine industrial biologics environment. You will find several major enabling innovations in the quest for a complete picture of biological products for regulatory approval and compliance in BioPharma Compass 1.1 such as:
Bruker has pioneered the field of novel mass spectrometry techniques for the direct measurement and sequencing of intact proteins. The industry-leading highest resolution maXis ESI-QqTOF spectra available at maximum sensitivity for trace impurities, patented top-down ISD-T3 sequencing on Flex series MALDI TOF/TOF and best-in-class amazon ETD ion-trap technology for PTM analysis are all critical steps in a complete understanding of the composition of a biotherapeutic. Now, BioPharmaCompass 1.1 enables biotech and pharma customers to manage information from any or all of these unique capabilities, dramatically speeding the licensing and production of biological drugs.
For more information on BioPharmaCompass 1.1, please go to: